Literature DB >> 4041

Platelet aggregation in portal cirrhosis.

H S Ballard, A J Marcus.   

Abstract

Primary and secondary platelet aggregation in response to adenosine diphosphate was studied in 24 patients with portal (Laënnec) cirrhosis and compared with platelet aggregation in 14 normal subjects. In 12 patients with cirrhosis, platelet aggregation was diminished when compared to controls. Of the 12 patients with impaired aggregation, 6 had elevated levels of fibrinogen-fibrin degradation products (FDPs), 11 had thrombocytopenia, 10 had shortened euglobulin lysis times, 11 had prolonged bleeding times, 4 had hypofibrinogenemia, and all had prolonged thrombin clotting times. The data suggest that elevated levels of serum FDPs do not explain fully the impairment of platelet aggregation or the prolongation of the thrombin clotting time that was noted in patients with advanced liver disease. A possible explanation for the prolongation of the thrombin clotting time is the presence of "altered" plasma fibrinogen.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 4041

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Acquired abnormalities of platelet function.

Authors: 
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

2.  Bleeding time in patients with hepatic cirrhosis.

Authors:  J C Blake; D Sprengers; P Grech; P A McCormick; N McIntyre; A K Burroughs
Journal:  BMJ       Date:  1990-07-07

3.  Clinical application of a new in vitro bleeding time device on surgical patients.

Authors:  T Tsujinaka; T Itoh; Y Uemura; M Sakon; J Kambayashi; T Mori
Journal:  Jpn J Surg       Date:  1988-07

4.  Platelet function in chronic liver disease: relationship to disease severity.

Authors:  M H Rubin; M J Weston; P G Langley; Y White; R Williams
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

Review 5.  Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged.

Authors:  Armando Tripodi; Massimo Primignani; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2009-08-28       Impact factor: 3.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.